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Antihypertensive therapy, new-onset diabetes,
and cardiovascular disease
J. N. Basile
The prevalence of type 2 diabetes mellitus is increas-
ing worldwide. The number of people living with
diabetes is expected to more than double from 171
million in 2000 to 366 million by 2030 (1). In the
United States, an estimated 9.3% of adults aged
20 years or older have diabetes (6.5% diagnosed and
2.8% undiagnosed), a signiﬁcant increase
(p = 0.0002) from the 5.1% prevalence of diagnosed
diabetes in the previous decade. Increases have been
seen in all age groups, both sexes and all race⁄ethnic
groups (2).
Risk factors for the development of diabetes include
overweight or obesity, physical inactivity, hyperten-
sion, dyslipidaemia, family history, impaired glucose
tolerance and impaired fasting glucose. Type 2 diabe-
tes is an important risk factor for cardiovascular dis-
ease (3) and is regarded as a coronary heart disease
‘risk equivalent’ by the Adult Treatment Panel III of
the National Cholesterol Education Program (4). Indi-
viduals with type 2 diabetes have a two- to threefold
higher risk of cardiovascular disease than their non-
diabetic counterparts (5), and, in the United States,
the majority (65%) of deaths in people with diabetes
are due to heart disease and stroke (6). Diabetes is also
associated with a signiﬁcant increase in risk of con-
comitant hypertension and dyslipidaemia (7).
The higher incidence of cardiovascular disease in
patients with type 2 diabetes can be explained in part
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SUMMARY
Type 2 diabetes mellitus is a worldwide epidemic with considerable health and
economic consequences. Diabetes is an important risk factor for cardiovascular dis-
ease, which is the leading cause of death in diabetic patients, and decreasing the
incidence of diabetes may potentially reduce the burden of cardiovascular disease.
This article discusses the clinical trial evidence for modalities associated with a
reduction in the risk of new-onset diabetes, with a focus on the role of antihyper-
tensive agents that block the renin–angiotensin system. Lifestyle interventions and
the use of antidiabetic, anti-obesity, and lipid-lowering drugs are also reviewed.
An unresolved question is whether decreasing the incidence of new-onset diabetes
with non-pharmacologic or pharmacologic intervention will also lower the risk of
cardiovascular disease. A large ongoing study is investigating whether the treat-
ment with an oral antidiabetic drug or an angiotensin-receptor blocker will reduce
the incidence of new-onset diabetes and cardiovascular disease in patients at high
risk for developing diabetes.
Review Criteria
The information used to prepare this manuscript
was gathered by reviewing guidelines for treatment
of prediabetes and from a PubMed search using
the following keywords: ‘antihypertensive therapy’,
‘cardiovascular disease’, ‘impaired fasting glucose’,
‘impaired glucose tolerance’, ‘renin–angiotensin
system’ and ‘type 2 diabetes mellitus’. The major
randomised, controlled clinical trials evaluating the
capacity of lifestyle interventions, antidiabetic
drugs, lipid-lowering drugs, and antihypertensive
drugs on the delay of new-onset diabetes and
cardiovascular disease are reviewed herein.
Message for the Clinic
Evidence suggests that lifestyle modiﬁcations aimed
at weight reduction and increased physical activity
and antidiabetic pharmacologic interventions reduce
the risk of new-onset diabetes. Although there is
ample evidence that antihypertensive therapy with
RAS inhibitors is associated with a reduced risk of
new-onset diabetes compared with other classes of
antihypertensive drugs, the prognostic signiﬁcance
of this differential effect remains controversial. For
now, lifestyle measures and the reduction of global
cardiovascular disease risk may be a more effective
strategy to improve vascular health and limit insulin
resistance in patients with hypertension than
restricting the use of any particular antihypertensive
agent.
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656 doi: 10.1111/j.1742-1241.2009.02009.xby the increased prevalence of comorbid risk factors
(8,9). However, even after correction for these fac-
tors, diabetes confers a 1.5- to 4.5-fold increase in
risk of myocardial infarction in women, a 1.5- to
twofold increase in risk of myocardial infarction in
men, and a 1.5- to twofold increase in risk of death
in both sexes (10).
Chronic hyperglycaemia is the deﬁning characteris-
tic of diabetes and the target of antidiabetic therapy
but the beneﬁts of reducing elevated glucose values
and the speciﬁc target that should be achieved
remain uncertain. While maintenance of glycaemic
control has been shown to reduce the risk of micro-
vascular complications, including retinopathy,
nephropathy and neuropathy (11,12), studies of the
effect of glycaemic control on the risk of macrovas-
cular complications have produced conﬂicting
results. A meta-analysis of prospective cohort studies
that assessed the association between glycosylated
haemoglobin (A1C) levels and macrovascular disease
in patients with diabetes observed that, in patients
with type 2 diabetes, each one-percentage point
increase in A1C is associated with an 18% increase
in risk of cardiovascular disease (13). In the United
Kingdom Prospective Diabetes Study, intensive gly-
caemic control to an average A1C of 7% in patients
with type 2 diabetes over a 10-year follow-up period
reduced the risk of microvascular, but not macrovas-
cular, complications compared with an average A1C
of 7.9% (12). In the 6.5-year Diabetes Control and
Complications Trial (DCCT), intensive treatment
compared with conventional treatment in patients
with type 1 diabetes was associated with 76% and
54% reductions in the risk of development and pro-
gression of retinopathy, respectively (p < 0.001 for
both), but no reduction was noted in macrovascular
disease (11). It was, however, in the Epidemiology of
Diabetes Interventions and Complications Study, an
11-year followup to DCCT, where intensive treat-
ment reduced the risk of any cardiovascular disease
event by 42% (p = 0.02) and the risk of non-fatal
myocardial infarction, stroke, or death from cardio-
vascular disease by 57% (p = 0.02) (14).
Two recently published landmark trials – the
Action in Diabetes and Vascular Disease: Pretaraz
and Diamicron Modiﬁed Release Controlled Evalua-
tion (ADVANCE) (15) and the Action to Control
Cardiovascular Risk in Diabetes (ACCORD) (16) –
failed to demonstrate that intensive glycaemic control
reduces cardiovascular disease risk in those with
long-standing type 2 diabetes. In both the 5-year
ADVANCE trial and the planned 4- to 8-year
ACCORD trial, intensive glucose control (deﬁned as
a target A1C level < 6.5% in ADVANCE and < 6.0%
in ACCORD) had no signiﬁcant effects on the inci-
dence of cardiovascular disease events compared with
standard glucose control. Moreover, in ACCORD, a
signiﬁcant increase in all-cause mortality in the
intensive treatment group led to premature discon-
tinuation of that arm of the trial at 3.5 years. Taken
together, the results of ADVANCE and ACCORD
suggest that 7% remains an appropriate A1C target
in those with long-standing type 2 diabetes (17,18).
While the results of the previous trials (including
ADVANCE) conﬁrm the role of more aggressive gly-
caemic control in reducing the risk of microvascular
complications, the lack of effect on cardiovascular
disease events may have important implications for
our understanding of the pathogenesis and reversibil-
ity of macrovascular complications of diabetes.
Taken together, these results suggest the need for
earlier intervention in those with type 2 diabetes as
well as the need to address non-glycaemic comorbid
risk factors, such as hypertension and dyslipidaemia
(18).
New-onset diabetes and
cardiovascular disease
The current criteria for diagnosis of diabetes are a
fasting plasma glucose level ‡ 126 mg⁄dl, symptoms
of hyperglycaemia, and a casual plasma glucose level
‡ 200 mg⁄dl, or a 2-h postchallenge plasma glucose
level ‡ 200 mg⁄dl during an oral glucose tolerance
test; fasting plasma glucose < 100 mg⁄dl and 2-h
plasma glucose < 140 mg⁄dl are considered ‘normal’
(19). The intermediate hyperglycaemic state that does
not meet the threshold for diagnosis of overt diabetes
is termed ‘prediabetes’ and comprises impaired fast-
ing glucose (fasting plasma glucose 100–125 mg⁄dl)
and impaired glucose tolerance (2-h plasma glucose
140–199 mg⁄dl) (19). Prediabetes, which affects 57
million adults and children in the United States (20),
imparts an increased risk of both progression to
overt diabetes and cardiovascular disease (21) mak-
ing it a potential target for treatment.
A comparison of recommendations for treatment
of prediabetes by the American Diabetes Association,
American Heart Association and American College
of Endocrinology is attached (Table 1). For the pre-
vention or delay of type 2 diabetes in patients with
impaired fasting glucose or impaired glucose toler-
ance, the American Diabetes Association suggests
‘lifestyle counselling’ [weight loss of 5–10% and at
least 150 min⁄week of moderate activity (e.g. walk-
ing)]. In individuals at very high risk of developing
diabetes (the presence of impaired fasting glucose
and impaired glucose tolerance plus other risk fac-
tors), the addition of the oral antidiabetic drug met-
formin is recommended (19). The American Heart
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of new-onset diabetes in patients with the metabolic
syndrome and impaired fasting glucose or impaired
glucose tolerance include weight reduction, increased
physical activity, metformin, thiazolidinediones and
acarbose, an intestinal a-glucosidase inhibitor (4). In
a recently released consensus statement on the treat-
ment of patients with prediabetes, the American Col-
lege of Endocrinology recommends targeting
hyperglycaemia and comorbid risk factors, including
hypertension and dyslipidaemia, with lifestyle modiﬁ-
cations and add-on pharmacologic therapy, where
needed (22). Speciﬁcally, the guidelines, while short
of clinical trial evidence, recommend that patients
with prediabetes and hypertension be treated with
antihypertensive agents that include those that inhi-
bit the renin–angiotensin system (RAS) – angioten-
sin-converting enzyme (ACE) inhibitors and
angiotensin receptor blockers (ARBs)—to the same
blood pressure goal recommended for patients with
overt diabetes, i.e. < 130⁄80 mmHg. Likewise, the
consensus document recommends that lipid goals
in patients with prediabetes should be the same as
those with diabetes: low-density lipoprotein choles-
terol < 100 mg⁄dl, non-high-density lipoprotein cho-
lesterol < 130 mg⁄dl, and apolipoprotein
B < 90 mg⁄dl.
Lifestyle intervention
Lifestyle modiﬁcation aimed at weight loss has been
shown to be highly effective in preventing or delay-
ing the development of diabetes in high-risk subjects
(Table 2). In the Finnish Diabetes Prevention Study,
522 obese adults with impaired glucose tolerance
were randomised to a lifestyle intervention group of
individualised counselling aimed at reducing weight
Table 1 Recommendations for treatment of patients with pre-diabetes by the American Diabetes Association, American Heart Association and
American College of Endocrinology
American Diabetes Association (21) American Heart Association (4)* American College of Endocrinology (22)
Lifestyle Weight loss of 5–10% body
weight and 30 min⁄day
moderate-intensity physical activity
Weight loss of 7–10% body weight
within 6–12 months
‡ 30 min⁄day moderate-intensity exercise
Reduced intake of saturated fat
(< 7% of total calories),
trans fat, and dietary cholesterol
(< 200 mg⁄dl); total
fat 25–35% of total calories;
reduced intake of simple sugars
30–60 min moderate-intensity
physical activity⁄day at least 5 times⁄week
Low-fat diet with adequate ﬁbre
Glucose Metformin in patients with IFG and IGT
and any risk factors for diabetes
Addition of drug therapy
(e.g. acarbose, metformin) in patients
with MetS, worsening glycaemia, CVD,
NA fatty liver disease, history of
gestational diabetes or PCOS
Blood pressure BP < 140⁄90 mmHg
BP medication(s) as needed to achieve goal BP
BP < 130⁄80 mmHg
ACEI or ARB as ﬁrst-line agent
Lipids Depending on risk, LDL-C < 130,
< 100 or < 70 mg⁄dl; non-HDL-C < 160,
< 130 or < 100 mg⁄dl
Lipid-lowering drug therapy with possible
addition of ﬁbrate or nicotinic acid
LDL-C: < 100 mg⁄dl
Non-HDL-C: < 130 mg⁄dl
ApoB: < 90 mg⁄dl
Prothrombotic state Depending on risk, consider low-dose aspirin
therapy or clopidogrel when
aspirin is contraindicated
Aspirin in therapy unless patient is
at increased risk of GI, intracranial
or other haemorrhagic condition
ACEI, angiotensin converting-enzyme inhibitor; ApoB, apolipoprotein B; ARB, angiotensin receptor blocker; BP, blood pressure; GI, gastrointestinal; HDL-C, high-den-
sity lipoprotein cholesterol; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; LDL-C, low-density lipoprotein cholesterol; MetS, metabolic syndrome; NA,
non-alcoholic; PCOS, polycystic ovary syndrome. *American Heart Association guidelines pertain to patients with the metabolic syndrome, deﬁned as any three of the
following features: elevated waist circumference [‡ 102 cm (‡ 40 inches) in men or ‡ 88 cm (‡ 35 inches) in women], elevated triglycerides [‡ 150 mg⁄dl
(1.7 mmol⁄l)] or drug treatment for elevated triglycerides, reduced HDL-C [< 40 mg⁄dl (< 1.03 mmol⁄l) in men or < 50 mg⁄dl (< 1.3 mmol⁄l)] in women or drug
treatment for reduced HDL-C, elevated blood pressure (‡ 130⁄85 mmHg or antihypertensive drug treatment), elevated fasting glucose (‡ 100 mg⁄dl) or drug treat-
ment for elevated glucose. Risk factors for diabetes = age < 60 years, body mass index ‡ 35 kg⁄m
2, family history of diabetes in ﬁrst-degree relatives, elevated
triglycerides, reduced HDL-C, hypertension, glycosylated haemoglobin > 6.0%.
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After a mean follow-up of 3.2 years, the incidence of
diabetes was 11% in the intervention group com-
pared with 23% in the control group, a signiﬁcant
58% risk reduction (p < 0.001). Similar results were
seen in the Diabetes Prevention Program (DPP),
conducted in the USA, in which 3234 non-diabetic
obese patients with elevated fasting and postload
plasma glucose concentrations were randomised to
one of the three interventions: a lifestyle programme
with goals of ‡ 7% weight loss and ‡ 150 min of
physical activity⁄week; pharmacologic therapy with
metformin or placebo (24). After a mean 2.8 years,
lifestyle intervention reduced the incidence of new-
onset diabetes by 58% and metformin-based therapy
reduced the risk of diabetes by 31%, compared with
placebo (p < 0.001 for both comparisons).
Although neither the Finnish Diabetes Prevention
Study nor the DPP was designed to assess cardiovas-
cular disease beneﬁt, cardiovascular disease risk fac-
tors were reduced in both trials. In the Finnish
study, at the end of 1 year, patients in the interven-
tion group had signiﬁcantly greater reductions in
weight (p < 0.001), systolic (p = 0.007) and diastolic
(p = 0.02) blood pressure, serum triglycerides
(p = 0.001), and fasting plasma glucose levels
(p < 0.001) (23). In the DPP, the incidence of meta-
bolic syndrome was reduced by 41% in the lifestyle
group (p < 0.001) and by 17% in the metformin
group (p < 0.03) compared with placebo (25).
Table 2 Effects of lifestyle modiﬁcation and pharmacologic therapy with antidiabetic, anti-obesity and lipid-lowering drugs on the risk of new-
onset diabetes in selected key randomised trials
Study Comparators
Duration
(years)* Patient population
Relative risk
(95% CI) p-Value
Prespeciﬁed
end-point?
Lifestyle intervention
Finnish Diabetes
Prevention Study (23)
Lifestyle intervention
vs. placebo
3.2 522 obese patients with IGT 0.4 (0.3–0.7) < 0.001 Yes
DPP (24) Lifestyle intervention
vs. placebo;
metformin vs. placebo
2.8 3234 non-diabetic obese patients
with IFG and IGT
0.42 (0.34–0.52)
0.69 (0.57–0.83)
< 0.001
< 0.001
Yes
Antidiabetic drugs
TRIPOD (26) Troglitazone vs. placebo 2.5 (median) 266 Hispanic women with
previous gestational diabetes
0.45 (0.25–0.83) < 0.01 Yes
STOP-NIDDM (27) Acarbose vs. placebo 3.3 1368 patients with IGT 0.75 (0.63–0.90) 0.0015 Yes
DREAM (29) Rosiglitazone vs. placebo 3.0 (median) 5269 patients with IFG and⁄or IGT
but without CVD or renal disease
0.38 (0.33–0.44) < 0.0001 Yes
Anti-obesity drug
XENDOS (31) Orlistat (+lifestyle i
nterventions) vs.
placebo (+lifestyle
interventions)
4.0 3305 non-diabetic obese
(BMI ‡ 30 kg⁄m
2)
patients with normal or IGT
0.63 (0.46–0.86) 0.0032 Yes
Lipid-lowering drugs
WOSCOPS (32) Pravastatin vs. placebo 4.9 5974 non-diabetic men aged
45–64 years
with dyslipidaemia and no
history of MI
0.70 (0.50–0.99) 0.042 No
Heart Protection
Study (33)
Simvastatin vs. placebo 5.0 14,573 patients with occlusive
arterial disease
1.15 (0.99–1.34) ns Yes
LIPID (34) Pravastatin vs. placebo 6.0 6997 patients with dyslipidaemia 0.89 (0.70–1.13) ns No
ASCOT-LLA (35) Atorvastatin vs. placebo 3.3 (median) 19,342 hypertensive
patients with ‡ 3
other CVD risk factors
1.15 (0.91–1.44) ns Yes
*Mean years of follow-up unless indicated. ASCOT-LLA, Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm; BMI, body mass index; CAD, coronary artery
disease; CI, conﬁdence interval; CVD, cardiovascular disease; DPP, Diabetes Prevention Program; DREAM, Diabetes Reduction Assessment with Ramipril and Rosiglit-
azone Medication; HF, heart failure; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; LIPID, Long-Term Intervention with Pravastatin in Ischemic Dis-
ease; LVH, left ventricular hypertrophy; MI, myocardial infarction; ns, not signiﬁcant; STOP-NIDDM, Study to Prevent Non-Insulin-Dependent Diabetes Mellitus;
TRIPOD, Troglitazone in Prevention of Diabetes; WOSCOPS, West of Scotland Coronary Prevention Study; XENDOS, Xenical in the Prevention of Diabetes in Obese
Subjects.
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of diabetes
A number of studies have assessed the impact of dif-
ferent classes of antidiabetic drugs on prevention of
diabetes (Table 2) (26–28). New-onset diabetes was
reduced in the Study to Prevent Non-insulin-depen-
dent diabetes mellitus (STOP-NIDDM), in which
1368 patients with impaired glucose tolerance were
treated with acarbose or placebo (27). At 39-month
followup, new-onset diabetes occurred in 32% of
patients in the acarbose group vs. 42% in the placebo
group (risk ratio, 0.75; p = 0.0015). Treatment with
acarbose was also associated with an increase in
reversion to normoglycaemia. In a secondary analysis
of STOP-NIDDM, acarbose also reduced the inci-
dence of cardiovascular disease events from 4.7% to
2.1% (hazard ratio, 0.51; p = 0.03), mainly as a
result of a reduction in myocardial infarction (hazard
ratio, 0.09; p = 0.02) (28). Moreover, acarbose was
associated with a reduced incidence of new-onset
hypertension (hazard ratio, 0.66; p = 0.006), an
important cardiovascular disease risk factor.
Similar results were achieved in the glycaemic arm
of the Diabetes REduction Assessment with ramipril
and rosiglitazone Medication (DREAM) trial, in
which 5269 patients with impaired fasting glucose
and⁄or impaired glucose tolerance and no previous
cardiovascular disease or signiﬁcant renal disease
were randomised to treatment with rosiglitazone or
placebo (and ramipril or placebo) in a 2 · 2 factorial
design (29). During a median 3-year followup,
11.6% of patients in the rosiglitazone group and
26.0% in the placebo group developed the primary
composite outcome of new-onset diabetes or death
(hazard ratio, 0.40; p < 0.0001). When the compo-
nents of the primary outcome were analysed sepa-
rately, rosiglitazone was associated with a signiﬁcant
reduction in the incidence of new-onset diabetes
(10.6% vs. 25.5%; hazard ratio, 0.38), but rates of
all-cause mortality were similar in both treatment
groups. Reversion to normoglycaemia was signiﬁ-
cantly more common in the rosiglitazone group
(50.5% vs. 30.3%; hazard ratio, 1.71); however, there
was no signiﬁcant difference in cardiovascular disease
event rates between the treatment groups.
The Outcome Reduction with an Initial Glargine
Intervention (ORIGIN) may help to clarify the effect
of glycaemic control on cardiovascular disease risk.
In ORIGIN, 12,612 people aged 50 years or older
with evidence of cardiovascular disease and impaired
fasting glucose, impaired glucose tolerance or diabe-
tes were randomised to treatment with insulin glar-
gine or standard glycaemic care (and long-chain x-3
polyunsaturated fatty acids or placebo) to determine
the effect of these treatments on cardiovascular dis-
ease risk (30). The anticipated end date of the study
is October 2009.
The anti-obesity drug orlistat, an inhibitor of pan-
creatic and gastrointestinal lipases, has been shown
to reduce the risk of new-onset diabetes (Table 2). In
the 4-year Xenical in the Prevention of Diabetes in
Obese Subjects trial, which included 3305 non-dia-
betic obese (body mass index ‡ 30 kg⁄m
2) individu-
als with normal or impaired glucose tolerance,
orlistat plus lifestyle interventions reduced the inci-
dence of new-onset diabetes by 37.3% (p = 0.0032)
compared with placebo plus lifestyle intervention
(31). The orlistat group also experienced signiﬁcantly
greater reductions in systolic and diastolic blood
pressures, low-density lipoprotein cholesterol, and
fasting blood glucose levels and a signiﬁcantly greater
increase in high-density lipoprotein cholesterol levels.
Although lipid-lowering agents such as statins have
been shown to reduce the risk of cardiovascular dis-
ease in patients with diabetes, post hoc analyses of
placebo-controlled trials have reported conﬂicting
results regarding the effects of statins on new-onset
diabetes (Table 2). In the 4.9-year West of Scotland
Coronary Prevention Study, which included 5974
non-diabetic men aged 45–64 years with dyslipida-
emia and no prior history of myocardial infarction,
pravastatin reduced the incidence of new-onset dia-
betes by 30% (p = 0.042) compared with placebo
(32). By contrast, in the Heart Protection Study (33),
the Long-Term Intervention with Pravastatin in
Ischemic Disease (34), and the Anglo-Scandinavian
Cardiac Outcomes Trial-Lipid Lowering Arm (35),
statin therapy had no impact on the development of
diabetes.
Role of antihypertensive agents
Patients at high risk for developing diabetes are likely
to also be hypertensive. Indeed, individuals with ele-
vated blood pressure are 2.5–5 times more likely
than their normotensive counterparts to develop type
2 diabetes (36,37). Until relatively recently, discus-
sions regarding the use of antihypertensive agents
and diabetes focused on the negative metabolic
effects of b-blockers and diuretics (38). More
recently, however, attention has been focused on the
potential metabolic beneﬁts of RAS inhibition with
ACE inhibitors and ARBs.
The effects of the b-blocker atenolol with or with-
out a thiazide diuretic (bendroﬂumethiazide) were
evident in the Anglo-Scandinavian Cardiac Outcomes
Trial-Blood Pressure Lowering Arm (ASCOT-BPLA)
(39). In the 5.5-year trial, which included 15,257
patients with hypertension and at least three other
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calcium channel blocker (CCB) amlodipine (with or
without the ACE inhibitor perindopril) was associ-
ated with a 16% reduction in risk of cardiovascular
disease events and a 30% reduction in risk of new-
onset diabetes compared with treatment with ateno-
lol (± bendroﬂumethiazide) (39). However, a new
subgroup analysis of ASCOT-BPLA concluded that,
along with baseline fasting plasma glucose and body
mass index, the use of atenolol ± diuretic was among
the major determinants of risk of new-onset diabetes
(40). The authors propose that the reduction in dia-
betes associated with the amlodipine-based regimen
may be caused by the metabolically protective effect
of perindopril combined with the neutral effects of
amlodipine, in contrast to the negative metabolic
effects of both atenolol and bendroﬂumethiazide.
Analyses of several clinical trials using antihyper-
tensive agents in patients with and without hyperten-
sion have demonstrated that RAS blockade
signiﬁcantly reduces the risk of new-onset diabetes in
patients treated with ACE inhibitors (41–44) or
ARBs (45–48), compared with diuretics, b-blockers,
CCBs, or placebo (Table 3). These ﬁndings are con-
ﬁrmed by the results of two recent meta-analyses
(49,50). In the ﬁrst meta-analysis of 13 trials that
included 93,451 patients without diabetes at baseline,
randomisation to ACE inhibitor- or ARB-based ther-
apy was associated with a 26% reduction in risk of
developing diabetes (p < 0.001) (49). In the second,
Table 3 Effects of inhibition of the renin–angiotensin system on risk of new-onset diabetes in select key randomised controlled trials
Study Comparators
Duration
(years)* Patient population
Relative risk
(95% CI) p-Value
Prespeciﬁed
end-point?
ACE inhibitors
CAPPP (41) Captopril vs. b-blocker⁄
diuretic
6.1 10,985 hypertensive patients 0.79 (0.67–0.94) 0.007 Yes
HOPE (42) Ramipril vs. placebo 5 9297 patients with history of CAD, stroke,
PVD, for diabetes and ‡ 1 other CVD risk factor
0.66 (0.51–0.85) < 0.001 Yes
ALLHAT (43) Lisinopril vs. diuretic 4.9 33,357 hypertensive patients with ‡ 1
other CVD risk factor
0.70 (0.56–0.86) < 0.001 No
PEACE (44) Trandolapril vs. placebo 4.8 (median) 8290 with stable CAD 0.83 (0.72–0.96) 0.001 No
ASCOT-BPLA (39) Amlodipine (±perindopril)
vs. atenolol (±diuretic)
5.5 (median) 19,257 hypertensive patients with ‡ 3
other CVD risk factors
0.70 (0.63–0.78) < 0.0001 Yes
DREAM (51) Ramipril vs. placebo 3.0 (median) 5269 patients with IFG and⁄or IGT but without
CVD or renal disease
0.91 (0.80–1.03) ns Yes
ARBs
LIFE (45) Losartan vs. atenolol 4.8 9193 hypertensive patients with LVH 0.75 (0.63–0.86) 0.001 Yes
SCOPE (46) Candesartan vs.
placebo⁄other drugs
3.7 4964 hypertensive patients aged 70–89 years 0.81 (0.61–1.02) 0.09 No
CHARM (47) Candesartan vs. placebo 3.1 7599 patients with HF 0.78 (0.64–0.96) 0.02 Yes
VALUE (48) Valsartan vs. amlodipine 4.2 15,245 hypertensive patients with
high risk of CVD events
0.77 (0.69–0.86) < 0.0001 Yes
TRANSCEND (57) Telmisartan vs. placebo 4.7 (median) 5926 patients intolerant to ACE inhibitors
with CAD, PVD, CBVD or diabetes
with end-organ damage
0.85 (0.71–1.02) 0.081 Yes
ACE inhibitor⁄ARB combination
ONTARGET (56) Telmisartan vs. ramipril;
telmisartan + ramipril
vs. ramipril
4.7 (median) 25,620 patients with CAD, PVD, CBVD
or diabetes with end-organ damage
1.12 (0.97–1.29)
0.91 (0.78–1.06)
ns
ns
Yes
*Mean years of follow-up unless indicated. ACE, angiotensin-converting enzyme; ALLHAT, Antihypertensive and Lipid-Lowering treatment to Prevent Heart Attack
Trial; ARB, angiotensin receptor blocker; ASCOT-BPLA, Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm; CAD, coronary artery disease;
CAPP, Captopril Prevention Project; CBVD, cerebrovascular disease; CHARM, Candesartan in Heart failure – Assessment of Reduction in Morbidity and Mortality; CI,
conﬁdence interval; CVD, cardiovascular disease; DREAM, Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication; HF, heart failure; HOPE, Heart
Outcomes Protection Study; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; LIFE, Losartan Intervention For End-point reduction in hypertension; LVH,
left ventricular hypertrophy; ns, not signiﬁcant; ONTARGET, Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial; PEACE, Prevention of
Events with Angiotensin-Converting Enzyme Inhibition; PVD, peripheral vascular disease; SCOPE, Study on Cognition and Prognosis in the Elderly; TRANSCEND,
Telmisartan Randomised Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease; VALUE, Valsartan Long-term Use Evaluation.
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143,153 participants without diabetes at study outset,
ARBs and ACE inhibitors were associated with the
lowest proportion of subjects developing diabetes
during clinical trial follow-up compared with other
classes of antihypertensive agents (odds ratio, 0.57
for ARBs, p < 0.0001; and 0.67 for ACE inhibitors,
p < 0.0001, using initial diuretic therapy as a stan-
dard of comparison) (50). These results are limited,
however, by the fact that new-onset diabetes was not
a prespeciﬁed primary or secondary outcome mea-
sure in a number of the trials included in the analy-
sis.
Several recently completed trials using ACE inhibi-
tors or ARBs included new-onset diabetes as a pre-
speciﬁed outcome measure. In the hypertension arm
of the 3-year DREAM trial, the incidence of the pri-
mary composite end-point of new-onset diabetes or
death was similar in the ramipril and the placebo
groups (18.1% vs. 19.5%; hazard ratio, 0.91;
p = 0.15) (51). There was no signiﬁcant difference in
the incidence of new-onset diabetes or cardiovascular
disease in patients treated with ramipril compared
with placebo. Moreover, a new analysis of DREAM
found no difference in the rates of a prespeciﬁed sec-
ondary cardiorenal end-point in either treatment
group (52). The failure of ramipril to reduce the
incidence of new-onset diabetes and cardiovascular
disease in this trial may be explained by several fea-
tures of the study design, including the trial’s short
duration (median 3 years vs. median 4.5 years in
previous RAS blocker trials) and the relatively low-
risk proﬁle of trial participants (mean age 55 years,
mean blood pressure 136⁄83 mmHg; no history of
signiﬁcant cardiovascular disease or renal disease),
suggesting that the degree of baseline RAS activation
in the study participants was lower than that in the
previous trials. Moreover, DREAM was placebo con-
trolled, which reduced the possibility that the use of
diabetogenic b-blockers or diuretics as comparator
drugs confounded the results (53).
New-onset diabetes was a prespeciﬁed secondary
end-point in the Valsartan Long-Term Use Evalua-
tion (VALUE), which randomised 15,245 patients
aged 50 years or older with hypertension and high
risk of cardiovascular disease events to a mean of
4.2 years of valsartan- or amlodipine-based therapy
(48). Although there were no statistically signiﬁcant
differences in the incidence of the primary composite
cardiac end-point or in all-cause mortality, the inci-
dence of new-onset diabetes was 23% lower in the
valsartan group compared with the amlodipine group
(13% vs. 41%; hazard ratio, 0.77). A post hoc analysis
of the VALUE trial indicated that the risk of cardiac
morbidity (deﬁned as myocardial infarction or heart
failure) in patients who developed diabetes during
the 4.2-year followup was intermediate between that
of those who had diabetes at baseline and those who
did not develop diabetes at any point (54). Diabetes
at baseline was associated with a twofold increase in
risk of cardiac morbidity (hazard ratio, 2.20;
p < 0.0001), while new-onset diabetes was associated
with a 43% increase in risk of cardiac morbidity
(p = 0.0008), primarily due to increased risk of con-
gestive heart failure. Nonetheless, there was no differ-
ence in risk of the primary composite end-point of
cardiac morbidity and mortality between those who
developed new-onset diabetes and those who did not
(hazard ratio, 1.10; p = 0.3447). Interestingly, new-
onset diabetes was also associated with a decreased
risk of all-cause mortality (hazard ratio, 0.61;
p = 0.0001), possibly due to the increased use of
aspirin, b-blockers, diuretics and statins in patients
who developed diabetes compared with those who
remained normoglycaemic (54,55).
New-onset diabetes was a secondary end-point in
both the Ongoing Telmisartan Alone and in Combi-
nation with Ramipril Global Endpoint Trial (ON-
TARGET) (56) and the Telmisartan Randomised
Assessment Study in ACE Intolerant Subjects with
Cardiovascular Disease (TRANSCEND) (57). The
similarly designed 56-month trials both included
high-risk patients with coronary, peripheral, or cere-
brovascular disease or diabetes with end-organ dam-
age and shared the primary composite outcome of
cardiovascular disease death, myocardial infarction,
stroke or hospitalisation for heart failure. In
ONTARGET, which randomised 25,620 patients to
ramipril, telmisartan or a combination of the two
drugs, the primary outcome occurred at similar rates
in the three treatment groups. Likewise, although
new-onset diabetes was least common in the combi-
nation therapy group (6.1% for the combination vs.
6.7% in the ramipril group and 7.5% in the telmisar-
tan group), the differences were not signiﬁcant (56).
TRANSCEND compared telmisartan to placebo in
5926 patients intolerant to ACE inhibitors. Telmisar-
tan had placebo-like tolerability. Despite a 4-mmHg
weighted difference in systolic blood pressure in
favour of telmisartan over placebo, the primary out-
come occurred at similar rates in both treatment
groups. Although new-onset diabetes occurred less
frequently in the telmisartan group, the difference
was not signiﬁcant (57). Whether this occurred
because of the excellent use of background therapy
that minimised any incremental beneﬁt that telmisar-
tan might provide remains unclear.
Recent analyses of metabolic and clinical outcomes
in non-diabetic patients in the Antihypertensive and
Lipid-Lowering Treatment to Prevent Heart Attack
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RAS inhibitors compared with diuretics but fail to
demonstrate a commensurate reduction in cardiovas-
cular disease events. ALLHAT, which did not include
new-onset diabetes as a prespeciﬁed outcome, rando-
mised patients aged 55 years or older with stage 1 or
stage 2 hypertension and at least one additional car-
diovascular disease risk factor to chlorthalidone,
amlodipine or lisinopril for a mean of 4.9 years (43).
Among patients without diabetes at baseline, the
incidence of diabetes at 4 years was the greatest with
chlorthalidone (11.6%), lower with amlodipine
(9.8%; p = 0.04 vs. chlorthalidone), and the lowest
in those treated with lisinopril (8.1%; p < 0.001 vs.
chlorthalidone) (43). However, in patients with the
metabolic syndrome at baseline, the incidence of
new-onset diabetes was almost twice as high as in
those without the metabolic abnormality at baseline:
17.1% in the chlorthalidone group, 16.0% in the am-
lodipine group and 12.6% in the lisinopril group
(p < 0.05 for lisinopril vs. chlorthalidone), compared
with rates of 7.7%, 4.2% and 4.7% for chlorthali-
done, amlodipine and lisinopril, respectively
(p < 0.05 for both amlodipine and lisinopril vs.
chlorthalidone) (58). Despite these differences, the
risk of combined cardiovascular disease events was
similar in those with the metabolic syndrome as in
those without, and in those who developed diabetes
and in those who did not (58). In a separate sub-
group analysis that compared cardiovascular disease
outcomes by race in non-diabetic patients with and
without the metabolic syndrome, long-term cardio-
vascular outcomes were similar across the treatment
groups, with the lack of cardiovascular beneﬁt espe-
cially striking in black patients with the metabolic
syndrome (59).
These analyses have not resolved the controversy
regarding the relationship between new-onset dia-
betes and cardiovascular disease risk and have led
some investigators to question whether diuretic- or
b-blocker-associated diabetes confers the same clin-
ical implications as new-onset diabetes that devel-
ops outside the setting of antihypertensive therapy
(60).
Further clariﬁcation of the comparative value of
antihypertensive combinations comparing the use of
a glucose neutral agent such as a CCB with a thia-
zide-type diuretic will come from the Avoiding Car-
diovascular Events Through Combination Therapy in
Patients Living With Systolic Hypertension trial. In
this trial, the high-risk hypertensive patients were
initially randomised to a ﬁxed-dose combination of
either an ACE inhibitor⁄thiazide-type diuretic or an
ACE inhibitor⁄CCB. New onset diabetes is a prespec-
iﬁed secondary end-point (61).
The question of whether preventing new-onset
diabetes is associated with a reduction in cardiovas-
cular disease events may be resolved with the results
of two ongoing large-scale clinical trials – Nateglinide
And Valsartan in Impaired Glucose Tolerance Out-
comes Research (NAVIGATOR) (62) and ACE
Inhibitor-based vs. Diuretic-based Antihypertensive
Primary Treatment in Patients with PreDiabetes
(ADaPT) (63). NAVIGATOR is a multinational,
double-blind, placebo-controlled, 2 · 2 factorial
study to determine the effects of the meglitinide an-
tidiabetic drug nateglinide and of valsartan on two
primary outcomes: prevention of new-onset diabetes
and prevention of cardiovascular disease events
(death, myocardial infarction, stroke and hospitalisa-
tion for heart failure). A total of 9306 participants
aged 50 years or older with impaired fasting glucose
and known cardiovascular disease or aged 55 years
or older with impaired glucose tolerance and 1 or
more cardiovascular disease risk factors were rando-
mised in a 1:1:1:1ratio to one of four possible
treatment combinations: nateglinide with valsartan,
nateglinide with valsartan-placebo, nateglinide-pla-
cebo with valsartan or nateglinide-placebo with val-
sartan-placebo. The results of this events-driven trial
are expected to be reported in 2009 (62). ADaPT,
which includes 2015 patients with hypertension,
impaired fasting glucose, and A1C 6–6.5%, is an
open-label trial designed to compare the effect on
new-onset diabetes of antihypertensive treatment
based on ramipril vs. treatment based on diuretics or
b-blockers. The results of the 4-year study are
expected in 2010 (63).
In the interim, the effects of antihypertensive ther-
apy and the presence of comorbid risk factors on the
risk of new-onset diabetes and cardiovascular disease
should be carefully evaluated for each patient.
Indeed, in post hoc analyses of ASCOT-BPLA (40)
and VALUE (64), baseline fasting plasma glucose
level and body mass index – two measurable, modiﬁ-
able risk factors – were the strongest predictors of
new-onset diabetes. In ASCOT-BPLA, randomisation
of the amlodipine ± perindopril treatment arm was
the strongest protective factor (40), highlighting the
importance of including a RAS inhibitor as part of
the antihypertensive regimen in patients at high risk
for diabetes and cardiovascular disease.
Possible mechanisms
The mechanisms by which RAS inhibition reduces
the development of diabetes remain to be established.
ACE inhibitors and ARBs improve insulin sensitivity,
possibly caused by their vasodilatory effects, which
result in increased blood ﬂow and increased insulin
delivery to peripheral skeletal muscles (65–67). ACE
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metabolism by enhancing insulin receptor signalling
in skeletal muscle and fat cells (68). RAS blockade is
associated with a reduction in renal potassium loss,
which may lead to enhanced b-cell secretion of insu-
lin (66,68) and may protect pancreatic islets from
glucotoxicity and oxidative stress (67). In addition,
ARBs increase levels of adiponectin, an adipose-
derived protein thought to enhance insulin sensitivity
(67,69). Finally, some ARBs activate peroxisome pro-
liferator-activated receptor-c, a well-established target
for insulin-sensitising antidiabetic drugs (66,69).
Conclusions
Diabetes is a worldwide epidemic with the substan-
tial health ramiﬁcations. Because cardiovascular dis-
ease is the leading cause of death in patients with
diabetes, the prevention of diabetes has the potential
to reduce the burden of cardiovascular disease. Evi-
dence suggests that lifestyle modiﬁcations aimed at
weight reduction and increased physical activity and
antidiabetic pharmacologic interventions reduce the
risk of new-onset diabetes. Although there is ample
evidence that antihypertensive therapy with RAS
inhibitors is associated with a reduced risk of new-
onset diabetes compared with other classes of antihy-
pertensive drugs, the prognostic signiﬁcance of this
differential effect remains controversial. No study
using antihypertensive therapy has yet demonstrated
a commensurate reduction in cardiovascular disease
risk, and secondary analyses of trials of RAS blockers
have provided conﬂicting results. It appears reason-
able to avoid traditional b-blocker and thiazide-type
diuretic therapy in the minority of patients who have
impaired fasting glucose or impaired glucose toler-
ance and whose blood pressure can be controlled on
single-agent antihypertensive therapy. In these
patients, the use of ACE inhibitor and ARB therapy,
like in those with the metabolic syndrome, may have
an advantage in decreasing the subsequent risk for
new-onset diabetes. When blood pressure is not
effectively controlled with ACE inhibitor or ARB
therapy, the addition of a thiazide-type diuretic is
clearly indicated as the beneﬁts of achieving blood
pressure control appear to outweigh any negative
effects on glucose metabolism. Whether a CCB
should be added before a thiazide-type diuretic
remains uncertain. The results of the large-scale
NAVIGATOR study may help resolve the issue of
whether treatment of high-risk patients with an
antidiabetic drug or an ARB reduces the incidence of
new-onset diabetes and cardiovascular disease.
For now, lifestyle measures including weight loss
and exercise as well as the importance of addressing
global cardiovascular disease risk through the use of
statin and aspirin therapy may be a more effective
strategy to improve vascular health and limit insulin
resistance in patients with hypertension. Additionally,
achieving blood pressure control with agents that do
not worsen insulin resistance should be attempted;
failing that, vasodilating b-blockers and low-dose
diuretics must be used to reduce risk. Physicians
should be aware that in most cases multiple antihy-
pertensive agents will be needed. While keeping
serum potassium levels normal, diuretics should be
considered when blood pressure goals have not been
achieved in patients with impaired fasting glucose.
When used in this setting, although new-onset diabe-
tes may be more likely to occur, cardiovascular out-
comes are still improved by achieving additional
blood pressure reduction.
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